Wasko, U. N., Jiang, J., Dalton, T. C., Curiel-Garcia, A., Edwards, A. C., Wang, Y., Lee, B., Orlen, M., Tian, S., Stalnecker, C. A., Drizyte-Miller, K., Menard, M., Dilly, J., Sastra, S. A., Palermo, C. F., Hasselluhn, M. C., Decker-Farrell, A. R., Chang, S., Jiang, L., … Olive, K. P. (2024). Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature, 629(8013), 927–936. https://doi.org/10.1038/s41586-024-07379-z

Fu, J., Li, S., Liu, G., MA, H., Marcireau, C., Mapara, M., & Lentzsch, S. (2023). Synergistic Anti-Tumor Effects in RAS Mut Multiple Myeloma By Targeting MAP4K2 and RAS Pathways. Blood, 142(Supplement 1), 6618–6618. https://doi.org/10.1182/blood-2023-190740

Hughes, M. S., Leng, S., Chakraborty, R., Bhutani, D., Mapara, M., Raza, S., & Lentzsch, S. (2023). Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up. Blood, 142(Supplement 1), 6576–6576. https://doi.org/10.1182/blood-2023-182842

Dhodapkar, M. V., Alsina, M., Berdeja, J. G., Patel, K. K., Richard, S., Vij, R., Leleu, X., Egan, D. N., Bergsagel, P. L., Reshef, R., Usmani, S. Z., Truppel-Hartmann, A., Basudhar, D., Thompson, E., Zheng, X., Eliason, L., Zhong, X., Greggio, C., Tran, S., … Siegel, D. S. (2023). Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up. Blood, 142(Supplement 1), 2101–2101. https://doi.org/10.1182/blood-2023-173970

Jagannath, S., Richter, J., Dhodapkar, M. V., Hoffman, J. E., Lee, H. C., Suvannasankha, A., Shah, M. R., Lentzsch, S., Zonder, J. A., Baz, R., Maly, J. J., Namburi, S., Wu, K. L., Pianko, M., Ye, J. C., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Bumma, N. (2023). Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study. Blood, 142(Supplement 1), 4746–4746. https://doi.org/10.1182/blood-2023-177968

Kim, S., Carvajal, R., Kim, M., & Yang, H. W. (2023). Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma. Cell Reports, 42(6), 112570. https://doi.org/10.1016/j.celrep.2023.112570